期刊文献+

包膜病毒样颗粒疫苗研究进展 被引量:4

Progress in research on enveloped VLP vaccines
下载PDF
导出
摘要 病毒样颗粒(VLPs)是指由病毒一个或几个结构蛋白自行组装成不含病毒基因组且不能复制、不具有感染能力的病毒样蛋白颗粒,形态结构上类似完整病毒,具有与完整病毒相似的免疫原性。VLPs可以分为两大类:无包膜VLPs和包膜VLPs,包膜VLPs被源于宿主细胞的脂质包膜包裹,包膜表面含有保护性抗原纤突。主要就包膜病毒样颗粒疫苗的结构、重组表达及免疫原性等方面的研究进展进行了综述。 Virus-like particles (VLPs) consist of one or more viral coat proteins that spontaneously self-assemble into parti- cles that are antigenically indistinguishable from infectious virus or subviral particles. VLPs are non-infective and non-repli- cating, since they are essentially devoid of infectious genetic material. Based on the structure of their parental viruses, VLPs can be divided into two major categories: non-enveloped VLPs and enveloped VLPs. Enveloped VLPs are shells assembled from the capsid and/or envelope protein(s) of enveloped viruses surrounded with a lipid membrane known as the viral envelope. This envelope is derived from the host cell plasma membrane in a process termed "budding". This paper mainly illustrates the progress on enveloped VLPs, including structure, expression system and immunogenicity.
出处 《微生物学免疫学进展》 2015年第3期58-62,共5页 Progress In Microbiology and Immunology
关键词 包膜 病毒样颗粒 表达系统 免疫原性 佐剂 Envelop Virus-like particles(VLPs) Expression system Immunogenicity Adjuvant
  • 相关文献

参考文献38

  • 1Win SJ,Ward VK,Dunbar PR,et al.Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway[J].Immunol Cell Biol,2011,89(6):681-688.
  • 2Kushnir N,Streatfield SJ,Yusibov V.Virus-like particles as a highly efficient vaccine platform:diversity of targets and production systems and advances in clinical development[J].Vaccine,2012,31(1):58-83.
  • 3Franco D,Liu W,Gardiner DF,et al.CD40L-containing viruslike particle as a candidate HIV-1 vaccine targeting dendritic cells[J].J Acquir Immune Defic Syndr,2011,56(5):393-400.
  • 4Pushko P,Pumpens P,Grens E,et al.Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures[J].Intervirology,2013,56(3):141-165.
  • 5Sakuragi S,Goto T,Sano K,et al.HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae[J].Proc Natl Acad Sci USA,2002,99(12):7956-7561.
  • 6Mc Aleer WJ,Buynak EB,Maigetter RZ,et al.Human hepatitis B vaccine from recombinant yeast[J].Nature,1984,307(5947):178-180.
  • 7Baumert TF,Ito S,Wong DT,et al.Hepatitis C virus structural proteins assemble into viruslike particles in insect cells[J].J Virol,1998,72(5):3827-3836.
  • 8Kang SM,Song JM,Quan FS,et al.Influenza vaccines based on virus-like particles[J].Virus Res,2009,143(2):140-146.
  • 9Quan FS,Steinhauer D,Huang C,et al.A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs[J].Vaccine,2008,26(26):3352-3361.
  • 10Pushko P,Pearce MB,Ahmad A,et al.Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes[J].Vaccine,2011,29(35):5911-5918.

二级参考文献40

  • 1Girard M P, Cherian T, Pervikov Y, et al. A review of vaccine research and development: human acute respira- tory infections[J]. Vaccine, 2005, 231 :5708-5724.
  • 2[ Reed C, Katz J M. Serological surveys for 2009 pan- demic influenza A H1NI[J]. Lancet, 2010, 375(9721) : 1062-1063.
  • 3Xu C, Bai T, Iuliano A D, et al. The seroprevalence of pandemic influenza H1N1 (2009) virus in China [J]. PLoS ONE , 2011,6(4) : e17919, doi:10. 1371/journal. pone. 0017919.
  • 4Latham T, Galarza J M. Formation of wild-type and chi- meric influenza virus-like particles following simultane- ous expression of only four structural proteins[J]. J Vir- oi, 2001, 75(13).. 6154-6165.
  • 5Gomez Puertas P, Albo C, Perez Pastrana E, et al. In- fluenza virus matrix protein is the major driving force in virus budding[J]. J Virol, 2000, 74(24) : 11538-11547.
  • 6Watanabe T, Watanabe S, Neumann G, et al. Immuno- genicity and protective efficacy of replication-incompe- tent influenza virus-like particles[J]. J Virol, 2002, 76 (2) : 767-773.
  • 7Latham T, Galarza J M. Formation of wild-type and Chi meric influenza virus-like particles following simultane- ous expression of only fours truetural proteins [J]. J Virol, 2001, 75(13): 6154-6165.
  • 8Chen B J,Leser G P,Morita E, et al. Influenza virus he- magglutinin and neuraminidase, but not the matrix pro- tein are required for assembly and budding of plasmi& derived virus-like particles[J]. J Virol, 2007, 81 (13): 7111-7123.
  • 9Crevar C J, Ross T M. Elicitation of protective immune responses using a bivalent HSN1 VLP vaccine[J]. J Virol, 2008, 5, 131.
  • 10BrightRA , CarterDM, ToapantaFR ,etal. Influ enza virus like particles elicit broader immune respon-ses than whole virion inactivated influenza virus or re- combinant hemagglutinin[J]. Vaccine, 2007, 25: 3871- 3878.

共引文献12

同被引文献29

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部